Fluctuations of epstein-barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up.
about
Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinomaEpstein-Barr virus antibodies and the risk of associated malignancies: review of the literatureEpstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesisEpstein-Barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan.Seroreactivity against Epstein-Barr virus (EBV) among first-degree relatives of sporadic EBV-associated nasopharyngeal carcinoma in Indonesia.Familial nasopharyngeal carcinomas possess distinguished clinical characteristics in southern China.Epstein-Barr virus BALF3 mediates genomic instability and progressive malignancy in nasopharyngeal carcinoma.Developing genetic epidemiological models to predict risk for nasopharyngeal carcinoma in high-risk population of China.Nasopharyngeal Epstein-Barr Virus Load: An Efficient Supplementary Method for Population-Based Nasopharyngeal Carcinoma Screening.Is maximum primary tumor diameter still a prognostic factor in patients with nasopharyngeal carcinoma treated using intensity-modulated radiotherapy?Incidence trend of nasopharyngeal carcinoma from 1987 to 2011 in Sihui County, Guangdong Province, South China: an age-period-cohort analysis.Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor originPositivity of both plasma Epstein-Barr virus DNA and serum Epstein-Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma.Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinomaExpression of Serum Sialic Acid, Early Antigen-IgA, and Viral Capsid Antigen-IgA in Nasopharynx Cancer Patients: The Diagnostic Implication of Combined AssaysExpression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis.Characterization of ELISA detection of broad-spectrum anti-Epstein-Barr virus antibodies associated with nasopharyngeal carcinoma.High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.EBV reactivation as a target of luteolin to repress NPC tumorigenesis.Subtype distribution and long-term titer fluctuation patterns of serum anti-Epstein-Barr virus antibodies in a non-nasopharyngeal carcinoma population from an endemic area in South China: a cohort study.Nasopharyngeal carcinoma incidence and mortality in China in 2009.The biological properties of different Epstein-Barr virus strains explain their association with various types of cancersBiomarker discovery of nasopharyngeal carcinoma by proteomics.Evaluation of Nasal and Nasopharyngeal Swab Collection for the Detection of Epstein-Barr Virus in Nasopharyngeal Carcinoma.Evaluation of seven recombinant VCA-IgA ELISA kits for the diagnosis of nasopharyngeal carcinoma in China: a case-control trial.iTRAQ-Based Quantitative Proteomic Analysis of Nasopharyngeal Carcinoma.Epstein-Barr Virus Rta-Mediated Accumulation of DNA Methylation Interferes with CTCF Binding in both Host and Viral Genomes.The Role of Epstein-Barr Virus DNA Load and Serology as Screening Tools for Nasopharyngeal Carcinoma.Sibship size, birth order and risk of nasopharyngeal carcinoma and infectious mononucleosis: a nationwide study in Sweden.Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in Southern China.Interval cancers in nasopharyngeal carcinoma screening: comparing two screening intervals after a negative initial screening result.Efficient translation of EBV DNA polymerase contributes to the enhanced lytic replication phenotype of M81 EBV.Lack of association between cigarette smoking and Epstein Barr virus reactivation in the nasopharynx in people with elevated EBV IgA antibody titres.Epstein-Barr virus association with peptic ulcer disease.An efficacy analysis for nasopharyngeal carcinoma screening of different screening intervals.Perspective: Contribution of Epstein-Barr virus (EBV) Reactivation to the Carcinogenicity of Nasopharyngeal Cancer Cells.The Relationship Between Environmental Factors and the Profile of Epstein-Barr Virus Antibodies in the Lytic and Latent Infection Periods in Healthy Populations from Endemic and Non-Endemic Nasopharyngeal Carcinoma Areas in China.The evolution of Epstein-Barr virus detection in nasopharyngeal carcinoma.
P2860
Q27016002-8FBFA368-C507-41B5-AE20-038063F3520FQ27021572-6F8F7503-FC3A-4E83-9705-D34CBC98D39DQ28079510-E40011E4-EC97-466B-BDA3-051E00DFABF5Q33847952-4C52DA7C-C384-49DE-8A47-34193186EF9EQ34202451-CAD796AF-9717-496F-96F6-45C39558C854Q34452737-CE75B02A-B914-44E6-AC96-2F9829B2F85AQ34483687-A9E43AA9-1618-4747-B7C1-87756480ECEEQ34606541-00B29B51-8E40-46D8-926D-59546E1BA3DFQ34671337-A2EB9EBD-4B43-4A41-BA98-BD517331CA1CQ35521570-799A44D0-61AB-42E6-A9D3-DA5BE51F800DQ36121218-5DE00C21-63C9-4021-BCBF-6C5EDF19D817Q36124331-29893F73-AA18-4799-96EA-299B611C014BQ36305182-F5FCF7A2-0293-4029-8181-C0A984B216FDQ36335515-27760329-E1AB-4790-A2A5-660C85A0D22AQ36425762-4BAB317E-E87E-44CD-8C34-CBE02A0DE38CQ36511863-6ABDFA38-0F38-4457-B0C7-10C74DBD2D2BQ36557221-6DB02CC4-0E8D-4D42-9921-8140331D7AF3Q37100066-6F914182-2442-4AD4-8084-1D9226941A66Q37109915-482D77E2-1EC9-44B7-A596-1DCBA7C5B0CBQ37178265-5CC182B1-2911-40DE-9C4F-DDE90F3C226BQ37354037-BF2F5D94-61F0-4920-AE3E-5E1BAE62CF8BQ37705818-7632AE2D-29C6-4A85-A978-7041C5AF6EA5Q38194579-C31CE955-118B-4FE7-AF4D-C64198E58133Q38612223-FB583061-32AB-41EC-982D-84A08DFE57C2Q38663245-7A1F1E1F-A74D-4C87-9545-611CA56B22A0Q38913291-35200480-FB45-4A39-9F05-167824FD796EQ40207035-E88EB93C-905C-4800-9D41-FDBBFB226CEDQ40770021-6C5AFA53-A416-4EE1-B263-C27A1CB2A9AEQ41272889-5D30B6B5-8E0A-4A7F-A563-6ACB9A94A414Q42240169-0D1FF93F-28FB-4191-8CB2-AA9F67651B20Q44562504-CDA98BE4-F7A3-45B1-AC3C-C8CCE8D78263Q44599305-35D8F814-4441-4106-977E-11EDDB31FFCEQ47269079-F7D5E18A-B4A5-483D-876B-6D86FB633ABBQ49996780-6B278526-4D74-4A80-B60D-07796914C9BEQ50991183-FF2EF451-086B-45C9-AA6E-2B3F055603ADQ51184991-307DACC0-999F-41C5-AEA0-AA3EB6DFB4D3Q54232271-6324E95F-DE32-462A-91A0-F894D979976FQ54243969-1C425274-9936-49B9-82F1-A239EF5753AAQ54254993-7BEBB183-427C-4196-9CE8-845D8512C81F
P2860
Fluctuations of epstein-barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Fluctuations of epstein-barr v ...... tudy with a 20-year follow-up.
@ast
Fluctuations of epstein-barr v ...... tudy with a 20-year follow-up.
@en
Fluctuations of epstein-barr v ...... tudy with a 20-year follow-up.
@nl
type
label
Fluctuations of epstein-barr v ...... tudy with a 20-year follow-up.
@ast
Fluctuations of epstein-barr v ...... tudy with a 20-year follow-up.
@en
Fluctuations of epstein-barr v ...... tudy with a 20-year follow-up.
@nl
prefLabel
Fluctuations of epstein-barr v ...... tudy with a 20-year follow-up.
@ast
Fluctuations of epstein-barr v ...... tudy with a 20-year follow-up.
@en
Fluctuations of epstein-barr v ...... tudy with a 20-year follow-up.
@nl
P2093
P2860
P1433
P1476
Fluctuations of epstein-barr v ...... tudy with a 20-year follow-up.
@en
P2093
Ming-Huang Hong
Qi-Hong Huang
Su-Mei Cao
Teng-Bo Huang
Wei-Hua Jia
Zhiwei Liu
P2860
P304
P356
10.1371/JOURNAL.PONE.0019100
P407
P50
P577
2011-04-22T00:00:00Z